<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03804060</url>
  </required_header>
  <id_info>
    <org_study_id>EDC-3599</org_study_id>
    <nct_id>NCT03804060</nct_id>
  </id_info>
  <brief_title>REperfusion With Cooling in CerebraL Acute IscheMia II</brief_title>
  <acronym>RECCLAIM-II</acronym>
  <official_title>A Multicenter, Prospective, Randomized-controlled Trial to Assess the Safety and Feasibility of Cooling as an Adjunctive Therapy to Thrombectomy and Reperfusion in Patients With Acute Cerebral Ischemia and Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ZOLL Circulation, Inc., USA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ZOLL Circulation, Inc., USA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine the feasibility and safety of achieving
      rapid hypothermia with the Proteus Intravascular Temperature Management (IVTM) system for
      patients experiencing acute ischemic stroke due to a large vessel occlusion.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 23, 2019</start_date>
  <completion_date type="Anticipated">September 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Test Arm patients achieving target temperature</measure>
    <time_frame>1 hour after thrombectomy</time_frame>
    <description>Percentage of Test Arm patients achieving target temperature &lt; 34 ºC within 1 hour of arterial puncture for thrombectomy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean door-to-Recanalization time</measure>
    <time_frame>perioperative</time_frame>
    <description>door-to-Recanalization time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of hemorrhagic conversion in each arm within 36 hours of Recanalization</measure>
    <time_frame>36 hours</time_frame>
    <description>Rate of hemorrhagic conversion</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Cooling + Recanalization</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The subjects will be considered to be enrolled in the Test Arm of the trial when all inclusion and exclusion criteria have been met, the informed consent form has been signed, and randomization to the Test Arm of the trial to allow cooling with the Proteus IVTM System before and after recanalization.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Recanalization only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The subjects will be considered to be enrolled in the Control Arm of the trial when all inclusion and exclusion criteria have been met, the informed consent form has been signed, and randomization to the Control Arm of the trial to allow recanalization only.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Proteus IVTM</intervention_name>
    <description>Cooling with the ZOLL® Circulation Proteus® catheter and the ZOLL® Intravascular Temperature Management system to initiate and maintain hypothermia for 6 hours as an adjunct to endovascular Recanalization.</description>
    <arm_group_label>Cooling + Recanalization</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Recanalization only</intervention_name>
    <description>Standard of Care for recanalization</description>
    <arm_group_label>Recanalization only</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All Inclusion Criteria must be answered YES for Patient to be eligible.

          1. Age ≥18 and ≤85;

          2. Signs and symptoms consistent with an acute ischemic stroke with anterior circulation
             large vessel occlusion (M1 MCA, carotid-terminus occlusion, Tandem occlusion allowed
             (Extracranial ICA+carotid T or M1 MCA) as determined by CT imaging; (i.e., hyper dense
             sign on non-contrast CT or CT angiogram);

          3. Ability to perform arterial puncture within 24 hours from symptom onset or last known
             normal (LKN);

          4. ASPECTS score of 5-10 on non-contrast CT of the brain if under 80 years; ASPECTS 8-10
             if age 80-85;

          5. Candidate for on label endovascular thrombectomy therapy;

          6. No contraindications to general anesthesia, conscious sedation or allergies to any
             components associated with the anticipated diagnostic or treatment procedures that
             cannot be treated;

          7. A pre-stroke modified Rankin Scale (mRS) of 0 or 1;

          8. Baseline CT scan shows no hemorrhage;

          9. NIH Stroke Scale (NIHSS) greater than or equal to 8;

         10. Patient is capable of complying with study procedures and agrees to complete all
             required study procedures, study visits and associated activities;

         11. Legally authorized representative must be able to understand and give written informed
             consent. Patient will assent if capable. Patient may be re-consented once it is
             established that there is no memory loss or cognitive impairment.

        Exclusion Criteria:

        All Exclusion Criteria must be answered NO to be eligible

          1. Female patients of childbearing potential who are known to be or may be pregnant;

          2. The patient has a known history of bleeding diathesis, coagulopathy, cryoglobulinemia,
             sickle cell anemia, or will refuse blood transfusions; history of genetically
             confirmed hypercoagulable syndrome

          3. The patient has a height of &lt; 1.5 meters (4 feet 11 inches);

          4. Use of warfarin with international normalized ratio (INR) &gt; 1.7;

          5. Blood clinical chemistry potassium (K+) &lt; 2.7;

          6. History of severe dementia and currently taking medication for cognitive impairment or
             behavior disorder;

          7. End stage renal disease on hemodialysis;

          8. Known presence of an inferior vena cava (IVC) filter;

          9. Contrast dye allergy with history of anaphylaxis, known serious sensitivity to
             contrast agents or any condition in which angiography is contraindicated;

         10. Known to have contraindications to radiological imaging;

         11. Known allergy to meperidine or buspar or dexmedetomidine;

         12. Sustained hypertension (SBP &gt; 185 or DBP &gt; 110 unable to be treated with a continuous
             infusion, e.g., nicardipine);

         13. Baseline CT/MR showing evidence of arterial vasculitis or dissection;

         14. Baseline CT/MR evidence of multiple vascular territory acute stroke;

         15. Excessive tortuosity of cervical vessels;

         16. Intracranial stent in area that may impact Recanalization;

         17. Presence of any other serious comorbidity that would be likely to impact life
             expectancy to less than 6 months or limit Patient cooperation or study compliance;

         18. Concurrent participation in an investigational clinical study (excluding registries)
             that has not completed the follow-up period or planned participation in another study
             within the next 3 months;

         19. Patient has any other condition(s) or circumstance(s) that, in the judgement of the
             investigator, might interfere with or impact the collection of high quality data, or
             with the completion of follow up requirements within the study windows;

         20. Patients without a legally authorized representative to sign the consent form will be
             excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rishi Gupta, MD, MBA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wellstar Medical Group</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shweta Kalpa, MD</last_name>
    <phone>408-419-2357</phone>
    <email>skalpa@zoll.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>WellStar Kennestone Regional Medical Center</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca McConnell, RN, BSN</last_name>
      <phone>470-793-4063</phone>
      <email>Rebecca.McConnell@wellstar.org</email>
    </contact>
    <investigator>
      <last_name>Rishi Gupta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lakshman Kalasapudi, M.A.</last_name>
      <phone>410-328-2913</phone>
      <email>lkalasapudi@som.umaryland.edu</email>
    </contact>
    <investigator>
      <last_name>Neeraj Badjatia, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ProMedica Toledo Hospital</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacy Parlette, RN, BSN</last_name>
      <phone>419-291-4068</phone>
      <email>Stacy.Parlette@ProMedica.org</email>
    </contact>
    <investigator>
      <last_name>Syed Zaidi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>January 9, 2019</study_first_submitted>
  <study_first_submitted_qc>January 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 15, 2019</study_first_posted>
  <last_update_submitted>May 6, 2020</last_update_submitted>
  <last_update_submitted_qc>May 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Therapeutic Hypothermia</keyword>
  <keyword>Cooling</keyword>
  <keyword>Stroke</keyword>
  <keyword>Neurological Acute Care</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

